-
公开(公告)号：US10921311B2
公开(公告)日：2021-02-16
申请号：US16070110
申请日：2017-01-13
Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH
Inventor： Kengo Takeuchi , Seiji Sakata , Yuki Togashi , Naoya Fujita , Ryohei Katayama
IPC: C07H21/04 , C12Q1/68 , G01N33/50 , C12N9/12 , G01N33/574 , C12N9/88 , C07K14/82 , A61K31/519 , A61P35/00 , A61K38/00 , C12N15/113 , C12N15/62 , C12Q1/6886 , C12Q1/6853 , C12Q1/686
Abstract: It is intended to reveal a polynucleotide serving as a novel causative gene of a cancer and, on the basis of this finding, to provide a method for detecting the polynucleotide or a polypeptide encoded thereby, a kit and a primer set for the detection, a method for screening for a substance that inhibits the polypeptide, and a pharmaceutical composition for the treatment of a cancer, containing the inhibiting substance. The detection method of the present invention detects a BRAF fusion protein or a fusion gene encoding the fusion protein, or a PXN or GMDS fusion protein or a fusion gene encoding the fusion protein in a digestive organ-derived sample obtained from a subject.
-
公开(公告)号：US12055538B2
公开(公告)日：2024-08-06
申请号：US17144776
申请日：2021-01-08
Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH
Inventor： Kengo Takeuchi , Seiji Sakata , Yuki Togashi , Naoya Fujita , Ryohei Katayama
IPC: C07H21/04 , A61K31/519 , A61K38/00 , A61P35/00 , C07K14/82 , C12N9/12 , C12N9/88 , C12N15/113 , C12N15/62 , G01N33/50 , G01N33/574 , C12Q1/6853 , C12Q1/686 , C12Q1/6886
CPC classification number: G01N33/5011 , A61K31/519 , A61K38/005 , A61P35/00 , C07K14/82 , C12N9/12 , C12N9/88 , C12N15/113 , C12N15/62 , C12Y207/11025 , C12Y402/01047 , G01N33/57446 , C12Q1/6853 , C12Q1/686 , C12Q1/6886
Abstract: It is intended to reveal a polynucleotide serving as a novel causative gene of a cancer and, on the basis of this finding, to provide a method for detecting the polynucleotide or a polypeptide encoded thereby, a kit and a primer set for the detection, a method for screening for a substance that inhibits the polypeptide, and a pharmaceutical composition for the treatment of a cancer, containing the inhibiting substance. The detection method of the present invention detects a BRAF fusion protein or a fusion gene encoding the fusion protein, or a PXN or GMDS fusion protein or a fusion gene encoding the fusion protein in a digestive organ-derived sample obtained from a subject.
-
公开(公告)号：US11530266B2
公开(公告)日：2022-12-20
申请号：US16626162
申请日：2019-06-14
Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH , API CO., LTD.
Inventor： Nobuhiko Gyobu , Naoya Fujita , Mamoru Kakino , Ai Kawashima , Shinya Fujihara , Naoki Goda
Abstract: The object of the present invention is to provide a humanized or mouse-human chimeric anti-podoplanin antibody or an antibody fragment containing the antigen-binding region thereof, and the object is achieved by providing an isolated humanized or mouse-human chimeric anti-podoplanin antibody which comprises a predetermined amino acid sequence, or an antibody fragment containing the antigen-binding region thereof.
-
公开(公告)号：US20210140943A1
公开(公告)日：2021-05-13
申请号：US17144776
申请日：2021-01-08
Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH
Inventor： Kengo Takeuchi , Seiji Sakata , Yuki Togashi , Naoya Fujita , Ryohei Katayama
IPC: G01N33/50 , C12N9/12 , G01N33/574 , C12N9/88 , C07K14/82 , A61K31/519 , A61P35/00 , A61K38/00 , C12N15/113 , C12N15/62
Abstract: It is intended to reveal a polynucleotide serving as a novel causative gene of a cancer and, on the basis of this finding, to provide a method for detecting the polynucleotide or a polypeptide encoded thereby, a kit and a primer set for the detection, a method for screening for a substance that inhibits the polypeptide, and a pharmaceutical composition for the treatment of a cancer, containing the inhibiting substance. The detection method of the present invention detects a BRAF fusion protein or a fusion gene encoding the fusion protein, or a PXN or GMDS fusion protein or a fusion gene encoding the fusion protein in a digestive organ-derived sample obtained from a subject.
-
公开(公告)号：US11419871B2
公开(公告)日：2022-08-23
申请号：US17014011
申请日：2020-09-08
Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH
Inventor： Ryohei Katayama , Ken Uchibori , Naoya Fujita
IPC: A61K31/506 , A61K31/662 , G01N33/574 , C12Q1/68 , A61P35/00 , A61K45/06
Abstract: A drug containing, as an active ingredient, a compound represented by ALK inhibitors such as brigatinib, AP26113-analog, and AZD3463 has been found to be effective against a non-small cell lung cancer having a point mutation at C797S in EGFR which has acquired a resistance to chemotherapy agents. Further, the drug used in combination with an anti-EGFR antibody demonstrates a notable suppression effect on the tumor growth. The drug has a potential to be a therapeutic agent effective against a non-small cell lung cancer which is resistant to gefitinib, a first generation therapeutic agent and osimertinib, a third generation therapeutic agent.
-
Patent Agency Ranking
公开(公告)号：US20210009683A1
公开(公告)日：2021-01-14
申请号：US16902618
申请日：2020-06-16
Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH
Inventor： Naoya Fujita , Takaya Sekiguchi , Satoshi Takagi
Abstract: A novel domain of Aggrus involved in the binding to CLEC-2 was searched for, and monoclonal antibodies recognizing the domain were obtained. The newly found PLAG4 domain is important for Aggrus binding to CLEC-2. Monoclonal antibodies recognizing this region were further developed. The present invention can provide novel Aggrus-CLEC-2 binding inhibitors, platelet aggregation inhibitors, cancer metastasis inhibitors, and tumor growth inhibitors using these antibodies.
-
公开(公告)号：US10813933B2
公开(公告)日：2020-10-27
申请号：US16302207
申请日：2017-05-17
Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH
Inventor： Ryohei Katayama , Ken Uchibori , Naoya Fujita
IPC: A61K31/506 , A61K31/662 , G01N33/574 , C12Q1/68 , A61P35/00 , A61K45/06
Abstract: A drug containing, as an active ingredient, a compound represented by ALK inhibitors such as brigatinib, AP26113-analog, and AZD3463 has been found to be effective against a non-small cell lung cancer having a point mutation at C797S in EGFR which has acquired a resistance to chemotherapy agents. Further, the drug used in combination with an anti-EGFR antibody demonstrates a notable suppression effect on the tumor growth. The drug has a potential to be a therapeutic agent effective against a non-small cell lung cancer which is resistant to gefitinib, a first generation therapeutic agent and osimertinib, a third generation therapeutic agent.
-
公开(公告)号：US10730939B2
公开(公告)日：2020-08-04
申请号：US15744507
申请日：2016-07-11
Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH
Inventor： Naoya Fujita , Takaya Sekiguchi , Satoshi Takagi
Abstract: A novel domain of Aggrus involved in the binding to CLEC-2 was searched for, and monoclonal antibodies recognizing the domain were obtained. The newly found PLAG4 domain is important for Aggrus binding to CLEC-2. Monoclonal antibodies recognizing this region were further developed. The present invention can provide novel Aggrus-CLEC-2 binding inhibitors, platelet aggregation inhibitors, cancer metastasis inhibitors, and tumor growth inhibitors using these antibodies.
-
公开(公告)号：US20190033293A1
公开(公告)日：2019-01-31
申请号：US16070110
申请日：2017-01-13
Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH
Inventor： Kengo Takeuchi , Seiji Sakata , Yuki Togashi , Naoya Fujita , Ryohei Katayama
Abstract: It is intended to reveal a polynucleotide serving as a novel causative gene of a cancer and, on the basis of this finding, to provide a method for detecting the polynucleotide or a polypeptide encoded thereby, a kit and a primer set for the detection, a method for screening for a substance that inhibits the polypeptide, and a pharmaceutical composition for the treatment of a cancer, containing the inhibiting substance. The detection method of the present invention detects a BRAF fusion protein or a fusion gene encoding the fusion protein, or a PXN or GMDS fusion protein or a fusion gene encoding the fusion protein in a digestive organ-derived sample obtained from a subject.
-
公开(公告)号：US20180237518A1
公开(公告)日：2018-08-23
申请号：US15744507
申请日：2016-07-11
Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH
Inventor： Naoya Fujita , Takaya Sekiguchi , Satoshi Takagi
IPC: C07K16/28 , G01N33/574 , C07K7/06 , A61P35/00
Abstract: A novel domain of Aggrus involved in the binding to CLEC-2 was searched for, and monoclonal antibodies recognizing the domain were obtained. The newly found PLAG4 domain is important for Aggrus binding to CLEC-2. Monoclonal antibodies recognizing this region were further developed. The present invention can provide novel Aggrus-CLEC-2 binding inhibitors, platelet aggregation inhibitors, cancer metastasis inhibitors, and tumor growth inhibitors using these antibodies.
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.018 seconds)
